Imagine a book made of three billion letters. There's just one typo, but it's the cause of a severe hereditary disease. Correcting such an error is much harder than it seems: for a long time, gene engineering tools often changed several neighboring letters along with the intended one. Now, scientists have taken a big step towards fixing only what is truly broken.
In a study published in Nature Biotechnology in 2026, a new system called snuABE, based on the ADAR enzyme, is presented. It allows for the replacement of one genetic 'letter'—adenine (A) with guanine (G)—with much greater precision than existing technologies.
Previous generations of base editors, such as ABE and ABE8e, were already a major breakthrough. They learned to modify individual DNA letters without cutting the double helix—which is significantly safer than classic CRISPR. But there was a problem: editors often affected several neighboring adenines at once. It was like a text editor fixing the intended letter but also changing a couple of adjacent characters without permission.
Research Briefing: ADAR-based DNA adenine base editing with single-nucleotide precision nature.com/articles/s4158… rdcu.be/fvJt2
The authors of the new work decided to use an unusual assistant: the ADAR enzyme. In nature, it doesn't work with DNA at all; its job is to edit RNA. The researchers created special guiding molecules, targetRNA, which literally guide ADAR to a single specific position. Thanks to this, the enzyme acts only on the selected nucleotide, barely affecting the neighbors.
Testing the technology on human HEK293T cells showed encouraging results. At 32 different genomic locations, the new system achieved an average efficiency of about 5.4%, and at some targets—up to 50%. Furthermore, off-target changes to neighboring bases were significantly rarer than with the ABE8e editor, and in many cases, practically absent.
The main value of this work is not even in the percentage of efficiency. For the first time, researchers have shown that the ADAR enzyme can be used for targeted DNA editing in mammalian cells, even though in its natural state it only interacts with RNA. This opens the way for creating a new generation of ultra-precise genetic editors capable of changing just one pre-selected nucleotide.
Such precision is particularly important for diseases caused by a single error in the genetic code. Some forms of sickle cell anemia, cystic fibrosis, hereditary retinal diseases, and several neurodegenerative diseases arise precisely from a single mutation. If we learn to fix only that, without affecting other parts of the genome, the safety of future gene therapies could significantly increase.
The history of genome editing resembles the evolution of surgery. Once, operations were crude and traumatic. Then, microsurgical instruments appeared, allowing for increasingly delicate work. Now, genetic engineering is going through a similar path: instead of broad interventions, scientists are gradually moving towards almost jewelry-like work at the level of individual DNA 'letters'.
It is important to remember: snuABE currently remains a laboratory development. All results were obtained in cell cultures. Research on animals, extensive safety testing, and the study of potential side effects are ahead, and only then will clinical trials on humans follow.
But even today, this work demonstrates how rapidly genetic engineering is developing. The more precise its tools become, the closer medicine gets to treating hereditary diseases at their root cause. And at the same time, the question becomes not only what we can change in the genome, but what we truly should change.
